Alamos Gold Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Alamos Gold

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: 1st.mate who wrote (501)	11/21/2001 10:52:51 AM
From: Al Collard	Read Replies (1) of 4470

HML-t... in the news: Globe says rival's bad news is good news for Hemosol Wednesday Nov 21 2001 The Globe and Mail reports in its Wednesday, Nov. 21, edition that Hemosol jumped 50 cents to $4.95 on the Toronto Stock Exchange Tuesday on extremely heavy volume of 1.3 million shares or 10 times the average daily turnover. The Globe's Market Movers column reports that the share action occurred after the United States Food and Drug Administration raised questions about a blood substitute product being developed by one of Hemosol's competitors, Northfield Laboratories of Evanston, Ill. Hemosol stock has been under pressure because of delays in U.S. testing of its Hemolink blood substitute. The stock has also suffered from analysts' perceptions that Hemosol was falling behind Northfield and Biopure of Cambridge Mass., in the race to market a replacement for blood transfusions. That view may be changing, says The Globe. Sprott Securities analyst Doug Janzen on Tuesday commenced coverage of Hemosol with a "speculative buy" rating and a 12-month target price of $12.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next